share_log
Benzinga ·  Apr 30 08:37
NRx Pharmaceuticals Announces Findings In Phase 2b/3 Clinical Trial Of NRX-101 Vs. Lurasidone For Treatment Of Suicidal Bipolar Depression, Says Demonstrated A 'Promising, Though Not yet Statistically Significant 33% Reduction in Suicidality Together With a 70% Reduction' In Symptoms Of Akathisia
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment